INNOVATION1 BIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0008 USD | -96.36% |
|
0.00% | -99.07% |
| Jan. 17 | Innovation1 Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023 | CI |
| 2023 | Innovation1 Biotech Inc. announced that it has received $0.15 million in funding | CI |
Valuation
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 9.832 | 0.8359 | 0.3977 | 0.5658 | 3.078 | 17.4 |
| Enterprise Value (EV) 1 | 9.107 | 0.8935 | 1.221 | 0.5884 | 3.429 | 17.58 |
| P/E ratio | -9.45 x | -3.81 x | -0.24 x | 0.65 x | -0.06 x | -1.22 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 586 x | 10.5 x | 337 x | 184 x | - | - |
| EV / Revenue | 543 x | 11.3 x | 1,034 x | 191 x | - | - |
| EV / EBITDA | -8.21 x | -1.34 x | -1.74 x | -2.29 x | -1.2 x | -13.9 x |
| EV / FCF | 17.7 x | -0.87 x | 1.2 x | -0.3 x | 0.12 x | -0.65 x |
| FCF Yield | 5.66% | -115% | 83.4% | -330% | 806% | -154% |
| Price to Book | 58.6 x | 35.1 x | -0.15 x | -2.49 x | 1.08 x | -5.06 x |
| Nbr of stocks (in thousands) | 431 | 438 | 187 | 189 | 20,020 | 20,470 |
| Reference price 2 | 22.79 | 1.910 | 2.125 | 3.000 | 0.1538 | 0.8500 |
| Announcement Date | 12/14/18 | 12/17/19 | 12/15/20 | 12/10/21 | 12/15/22 | 1/17/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0168 | 0.0792 | 0.001181 | 0.00308 | - | - |
| EBITDA 1 | -1.11 | -0.665 | -0.6999 | -0.257 | -2.858 | -1.266 |
| EBIT 1 | -1.11 | -0.6669 | -0.7025 | -0.2584 | -5.267 | -1.267 |
| Operating Margin | -6,619.34% | -841.52% | -59,486.88% | -8,390.94% | - | - |
| Earnings before Tax (EBT) 1 | -0.9755 | -0.1701 | -2.58 | 1.04 | -40.88 | -5.988 |
| Net income 1 | -0.9755 | -0.1701 | -2.58 | 1.04 | -40.88 | -5.988 |
| Net margin | -5,816.73% | -214.61% | -218,464.69% | 33,764.03% | - | - |
| EPS 2 | -2.411 | -0.5017 | -8.760 | 4.627 | -2.731 | -0.6975 |
| Free Cash Flow 1 | 0.515 | -1.03 | 1.019 | -1.943 | 27.66 | -27.01 |
| FCF margin | 3,070.93% | -1,299.5% | 86,260.37% | -63,087.47% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/14/18 | 12/17/19 | 12/15/20 | 12/10/21 | 12/15/22 | 1/17/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.06 | 0.82 | 0.02 | 0.35 | 0.18 |
| Net Cash position 1 | 0.72 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.0866 x | -1.176 x | -0.0876 x | -0.1229 x | -0.1415 x |
| Free Cash Flow 1 | 0.52 | -1.03 | 1.02 | -1.94 | 27.7 | -27 |
| ROE (net income / shareholders' equity) | -1,200% | -163% | 195% | -71.6% | -3,111% | 2,074% |
| ROA (Net income/ Total Assets) | -160% | -74.5% | -189% | -82.7% | -14.9% | -3.6% |
| Assets 1 | 0.6085 | 0.2283 | 1.366 | -1.257 | 274.1 | 166.5 |
| Book Value Per Share 2 | 0.3900 | 0.0500 | -14.40 | -1.210 | 0.1400 | -0.1700 |
| Cash Flow per Share 2 | 1.800 | 0.0400 | 0.1000 | 0.7300 | 0.0100 | 0 |
| Capex 1 | 0 | 0.01 | - | - | 0.85 | - |
| Capex / Sales | 14.71% | 8.28% | - | - | - | - |
| Announcement Date | 12/14/18 | 12/17/19 | 12/15/20 | 12/10/21 | 12/15/22 | 1/17/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -99.07% | 17.98K | |
| +137.37% | 5.68B | |
| +1.89% | 1.01B | |
| +2.19% | 982M | |
| +41.91% | 872M | |
| +25.27% | 819M | |
| +1.68% | 663M | |
| +0.54% | 610M | |
| -.--% | 600M | |
| +21.31% | 552M |
- Stock Market
- Equities
- IVBT Stock
- Financials Innovation1 Biotech Inc.
